Great to get clarity about DFU timeframe. Hopefully outcomes analysed and released by end of 2024. Only Phase1 but a positive here will give a valuable signal for a significant market opportunity. 30 patients a solid number for a phase 1.
As a potential regulatory strategy, I'd be thinking about a large phase2 thereafter which could support an accelerated approval through a successful surrogate endpoint given the FDA recent favourable standing on the AA pathway.
One milestone missed from last quarter is the first Kidney Transplant patient. Hopefully actioned and announced soon.
VFM
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.010(6.06%) |
Mkt cap ! $39.54M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $29.83K | 169.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 36293 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 2837 | 1 |
View Market Depth
| Last trade - 13.02pm 28/07/2025 (20 minute delay) ? |
| CYP (ASX) Chart |